10,000 Cancer Patients to Gain Fast-Track Access Through NHS Melanoma Vaccine Trial

Published on Spencer Knight via LinkedIn

The NHS in England is fast-tracking a cancer vaccine trial for melanoma through its Cancer Vaccine Launch Pad (CVLP) initiative. The investigational vaccine, iSCIB1+ (ImmunoBody), helps train the immune system to recognize and eliminate melanoma cells, aiming to prevent recurrence and support patients who don’t respond to immunotherapy.

Developed by Scancell, the trial is part of a broader NHS goal to provide personalized vaccine treatments to over 10,000 patients by 2030. Some participants are already reporting tumor shrinkage. Spencer Knight highlights the role of centralized access and collaboration in making these trials widely available across the country.

Read the full article via The Telegraph:

👉 Melanoma patients in England get fast-track access to cancer vaccine

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.